Profile data is unavailable for this security.
About the company
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
- Revenue in USD (TTM)247.54m
- Net income in USD3.73m
- Incorporated1982
- Employees730.00
- LocationMesa Laboratories Inc12100 W 6th AveLAKEWOOD 80228United StatesUSA
- Phone+1 (303) 987-8000
- Fax+1 (303) 987-8989
- Websitehttps://mesalabs.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myriad Genetics Inc | 824.50m | -365.90m | 431.07m | 2.70k | -- | 1.17 | -- | 0.5228 | -3.95 | -3.95 | 8.90 | 3.94 | 0.9509 | 8.53 | 6.97 | 305,370.40 | -42.20 | -15.51 | -50.95 | -18.02 | 69.93 | 69.98 | -44.38 | -23.60 | 2.26 | -7.79 | 0.2458 | -- | -1.56 | -- | -187.43 | -- | -- | -- |
| Standard Biotools Inc | 105.90m | -61.49m | 434.56m | 818.00 | -- | 1.02 | -- | 4.10 | -0.162 | -0.1973 | 0.2775 | 1.10 | 0.1795 | 1.80 | 4.52 | -- | -10.42 | -23.14 | -12.23 | -27.91 | 48.38 | 47.79 | -58.06 | -92.67 | 4.01 | -- | 0.0007 | -- | -6.24 | -9.19 | 57.05 | -- | -8.17 | -- |
| AngioDynamics, Inc. | 307.31m | -27.71m | 471.53m | 675.00 | -- | 2.70 | -- | 1.53 | -0.6731 | -0.6731 | 7.47 | 4.24 | 1.10 | 2.12 | 7.02 | 455,268.20 | -9.87 | -13.69 | -13.83 | -16.19 | 54.58 | 52.46 | -9.02 | -21.32 | 1.33 | -- | 0.0329 | -- | -3.76 | 2.06 | 81.56 | -- | -10.06 | -- |
| Orthopediatrics Corp | 227.41m | -45.61m | 481.05m | 562.00 | -- | 1.38 | -- | 2.12 | -1.96 | -1.96 | 9.74 | 13.93 | 0.4628 | 0.5149 | 4.83 | 404,644.10 | -9.28 | -5.87 | -9.97 | -6.44 | 71.73 | 74.27 | -20.06 | -16.55 | 3.52 | -5.96 | 0.2214 | -- | 37.65 | 23.06 | -80.33 | -- | 4.29 | -- |
| Neuropace Inc | 94.86m | -23.99m | 482.33m | 209.00 | -- | 26.20 | -- | 5.08 | -0.7535 | -0.7535 | 2.98 | 0.5564 | 0.9321 | 1.46 | 7.16 | 515,565.20 | -23.57 | -35.71 | -28.36 | -44.34 | 76.77 | 73.39 | -25.28 | -60.45 | 3.94 | -3.58 | 0.7603 | -- | 22.14 | 16.67 | 17.64 | -- | -8.15 | -- |
| Cerus Corp | 225.97m | -15.96m | 491.74m | 281.00 | -- | 8.00 | -- | 2.18 | -0.0848 | -0.0848 | 1.20 | 0.3201 | 1.12 | 1.99 | 8.35 | 804,163.70 | -7.91 | -20.38 | -12.30 | -31.96 | 60.50 | 61.15 | -7.09 | -25.37 | 1.29 | -1.04 | 0.5772 | -- | 7.78 | 16.51 | 44.20 | -- | -20.50 | -- |
| Pacific Biosciences of California Inc | 160.01m | -546.38m | 507.36m | 485.00 | -- | 94.84 | -- | 3.17 | -1.83 | -1.83 | 0.5334 | 0.0177 | 0.1565 | 1.96 | 5.08 | 329,907.20 | -53.45 | -22.47 | -57.35 | -24.29 | 33.97 | 33.11 | -341.47 | -214.45 | 4.47 | -21.70 | 0.9918 | -- | 3.89 | 15.19 | -76.34 | -- | 49.33 | -- |
| Mesa Laboratories Inc | 247.54m | 3.73m | 533.53m | 730.00 | 149.24 | 2.86 | 18.56 | 2.16 | 0.6471 | 0.6471 | 44.81 | 33.79 | 0.5678 | 3.40 | 6.28 | 339,097.30 | 0.8564 | -8.81 | 1.13 | -9.71 | 62.40 | 61.98 | 1.51 | -25.15 | 1.45 | 1.62 | 0.4709 | -- | 11.47 | 15.41 | 99.22 | -- | 24.60 | 0.00 |
| Orthofix Medical Inc | 822.31m | -92.19m | 543.15m | 1.61k | -- | 1.20 | -- | 0.6605 | -2.34 | -2.34 | 20.76 | 11.30 | 0.943 | 1.42 | 6.08 | 512,343.90 | -10.57 | -12.43 | -13.13 | -15.38 | 68.83 | 69.37 | -11.21 | -12.99 | 1.43 | -1.66 | 0.2803 | -- | 2.85 | 15.13 | 26.83 | -- | 7.31 | -- |
| Varex Imaging Corp | 854.40m | -67.70m | 551.82m | 2.40k | -- | 1.16 | -- | 0.6459 | -1.63 | -1.63 | 19.34 | 11.38 | 0.7032 | 1.85 | 6.00 | 356,000.00 | -5.55 | -0.3327 | -6.45 | -0.3955 | 34.15 | 33.16 | -7.89 | -0.4661 | 1.87 | 2.22 | 0.4321 | -- | 4.14 | 2.73 | -47.38 | -- | -0.5159 | -- |
| Beta Bionics Inc | 100.25m | -73.20m | 560.55m | 420.00 | -- | 1.95 | -- | 5.59 | -1.95 | -1.95 | 2.48 | 6.48 | 0.4191 | 2.55 | 6.34 | 238,692.90 | -30.60 | -- | -34.34 | -- | 55.40 | -- | -73.02 | -- | 7.96 | -- | 0.00 | -- | 53.94 | -- | -33.68 | -- | -- | -- |
| Cytek Biosciences Inc | 196.83m | -12.82m | 575.90m | 692.00 | -- | 1.51 | -- | 2.93 | -0.1011 | -0.1011 | 1.54 | 2.96 | 0.3992 | 1.86 | 3.60 | 303,746.90 | -2.60 | 0.3407 | -3.02 | 0.3811 | 53.46 | 58.12 | -6.51 | 0.8678 | 4.48 | -- | 0.0213 | -- | 3.85 | 28.20 | 50.44 | -- | 30.83 | -- |
| Embecta Corp | 1.08bn | 139.50m | 607.60m | 1.85k | 4.34 | -- | 3.36 | 0.5627 | 2.37 | 2.37 | 18.31 | -10.35 | 0.9757 | 2.27 | 6.35 | 583,621.60 | 12.61 | 16.69 | 16.60 | 22.65 | 63.17 | 66.74 | 12.92 | 15.71 | 1.87 | 3.18 | 1.79 | 13.07 | -3.80 | -0.1033 | 21.84 | -25.93 | -26.03 | -- |
| Anteris Technologies Global Corp | 2.14m | -84.32m | 632.98m | 136.00 | -- | 63.48 | -- | 295.91 | -2.34 | -2.34 | 0.0594 | 0.1025 | 0.1065 | 1.53 | 11.88 | 15,728.75 | -420.16 | -- | -1,527.00 | -- | 67.94 | -- | -3,945.70 | -- | 0.8032 | -- | 0.046 | -- | -1.16 | -- | -65.77 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Mesa Laboratories Inc's reporting currency: US Dollar USD
37.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 334.19k | 6.05% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 282.77k | 5.12% |
| Long Path Partners LPas of 31 Dec 2025 | 227.22k | 4.12% |
| Boston Partners Global Investors, Inc.as of 31 Dec 2025 | 213.38k | 3.86% |
| Select Equity Group LPas of 31 Dec 2025 | 206.44k | 3.74% |
| Ranger Investment Management LPas of 31 Dec 2025 | 205.26k | 3.72% |
| Geneva Capital Management LLCas of 31 Dec 2025 | 178.71k | 3.24% |
| Royce & Associates LPas of 31 Dec 2025 | 153.35k | 2.78% |
| Kennedy Capital Management LLCas of 31 Dec 2025 | 144.61k | 2.62% |
| Diamond Hill Capital Management, Inc.as of 31 Dec 2025 | 141.97k | 2.57% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
